A new peer-reviewed systematic review published in Diabetes, Obesity and Metabolism takes a close look at how diet and nutrition interact with GLP-1 and dual GIP/GLP-1 receptor agonist medications — a question that millions of people on drugs like Ozempic, Wegovy, Mounjaro, and Zepbound are asking but that science has largely left unanswered until now.
What the Research Examined
The systematic review focused specifically on patients using GLP-1 receptor agonists (GLP-1 RAs) and dual GIP/GLP-1 receptor agonists — the class of medications that includes semaglutide and tirzepatide — in combination with lifestyle interventions. Researchers noted that while these drugs are widely used to manage obesity, prediabetes, and type 2 diabetes, their nutritional implications have remained unclear. The review compiled and analyzed evidence from randomized clinical trials to address that gap.
Why Nutrition Matters on These Medications
GLP-1 medications work in part by slowing digestion and reducing appetite, which means people taking them often eat significantly less. While that drives weight loss, it also raises important nutritional questions: Are patients getting enough protein to preserve muscle mass? Are they meeting micronutrient needs on a reduced-calorie intake? The review's authors recognized these as open questions worth systematically examining — and the fact that it appeared in a major diabetes and obesity journal signals growing clinical interest in optimizing how patients eat while on these drugs, not just whether they lose weight.
What This Means for Patients
For people currently taking or considering GLP-1 medications, this research underscores a key point: what you eat alongside these drugs likely matters, not just how much you eat. Because the full findings beyond the abstract were not available in the source material, specific dietary recommendations from this review cannot be reported here. However, the study's framing — examining nutritional management as an adjunct to medication — reinforces that GLP-1 therapy is most effective as part of a broader lifestyle approach, not a standalone solution.
Key takeaway: A new systematic review in Diabetes, Obesity and Metabolism confirms that the nutritional implications of GLP-1 and dual GIP/GLP-1 medications are an active and important area of clinical research — and that diet quality, not just calorie reduction, deserves attention while on these drugs.
What to Watch Next
As the full findings of this systematic review become more widely available, clinicians and patients should look for specific guidance on protein intake, micronutrient supplementation, and meal composition strategies. Researchers and dietitians working in obesity medicine are increasingly focused on building evidence-based nutrition protocols that complement GLP-1 therapy — expect more targeted dietary guidelines to emerge as this field matures.
Frequently Asked Questions
Nutrition on GLP-1 therapy is a rapidly evolving area of research. As more findings emerge, your prescribing physician or a registered dietitian can help you apply the latest evidence to your specific health goals and medication regimen.
- Peer-reviewed systematic review, 'Dietary Strategies and Nutritional Management in Patients Receiving GLP-1 and Dual GIP/GLP-1 Receptor Agonists as Adjuncts to Lifestyle Interventions: A Systematic Review of Randomised Clinical Trials,' Diabetes, Obesity and Metabolism journal, date not specified in source material.